Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2.
BMI
BNT162b2
SARS-CoV-2
age
antibody
blood-group
gender
kinetic
serology
vaccine
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
21 Jun 2021
21 Jun 2021
Historique:
received:
07
06
2021
revised:
17
06
2021
accepted:
18
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Little is known about potential confounding factors influencing the humoral response in individuals having received the BNT162b2 vaccine. Blood samples from 231 subjects were collected before and 14, 28, and 42 days following coronavirus disease 2019 (COVID-19) vaccination with BNT162b2. Anti-spike receptor-binding-domain protein (anti-Spike/RBD) immunoglobulin G (IgG) antibodies were measured at each time-point. Impact of age, sex, childbearing age status, hormonal therapy, blood group, body mass index and past-history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were assessed by multivariable analyses. In naïve subjects, the level of anti-Spike/RBD antibodies gradually increased following administration of the first dose to reach the maximal response at day 28 and then plateauing at day 42. In vaccinated subjects with previous SARS-CoV-2 infection, the plateau was reached sooner (i.e., at day 14). In the naïve population, age had a significant negative impact on anti-Spike/RBD titers at days 14 and 28 while lower levels were observed for males at day 42, when corrected for other confounding factors. Body mass index (BMI) as well as B and AB blood groups had a significant impact in various subgroups on the early response at day 14 but no longer after. No significant confounding factors were highlighted in the previously infected group.
Sections du résumé
BACKGROUND
BACKGROUND
Little is known about potential confounding factors influencing the humoral response in individuals having received the BNT162b2 vaccine.
METHODS
METHODS
Blood samples from 231 subjects were collected before and 14, 28, and 42 days following coronavirus disease 2019 (COVID-19) vaccination with BNT162b2. Anti-spike receptor-binding-domain protein (anti-Spike/RBD) immunoglobulin G (IgG) antibodies were measured at each time-point. Impact of age, sex, childbearing age status, hormonal therapy, blood group, body mass index and past-history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were assessed by multivariable analyses.
RESULTS AND CONCLUSIONS
CONCLUSIONS
In naïve subjects, the level of anti-Spike/RBD antibodies gradually increased following administration of the first dose to reach the maximal response at day 28 and then plateauing at day 42. In vaccinated subjects with previous SARS-CoV-2 infection, the plateau was reached sooner (i.e., at day 14). In the naïve population, age had a significant negative impact on anti-Spike/RBD titers at days 14 and 28 while lower levels were observed for males at day 42, when corrected for other confounding factors. Body mass index (BMI) as well as B and AB blood groups had a significant impact in various subgroups on the early response at day 14 but no longer after. No significant confounding factors were highlighted in the previously infected group.
Identifiants
pubmed: 34205564
pii: microorganisms9061340
doi: 10.3390/microorganisms9061340
pmc: PMC8235462
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Microbiol Infect. 2021 Sep;27(9):1351.e5-1351.e7
pubmed: 33975007
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Endocrinol Diabetes Metab. 2020 Aug 14;4(1):e00176
pubmed: 32904932
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Med Microbiol. 2021 Aug;70(8):
pubmed: 34397348
Obesity (Silver Spring). 2020 Jun;28(6):1005
pubmed: 32237206
Clin Chim Acta. 2020 Oct;509:220-223
pubmed: 32562665
Vaccines (Basel). 2021 Apr 05;9(4):
pubmed: 33916489
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
Clin Chem. 2020 Aug 1;66(8):1104-1106
pubmed: 32484887
Vox Sang. 2021 Aug;116(7):766-773
pubmed: 33493365
PLoS One. 2013 Dec 11;8(12):e82779
pubmed: 24349359
Aging Cell. 2015 Jun;14(3):309-21
pubmed: 25720438
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
Trends Immunol. 2009 Jul;30(7):351-9
pubmed: 19540808
Vaccine. 2016 Jan 20;34(4):540-546
pubmed: 26667611
Clin Microbiol Rev. 2019 Mar 13;32(2):
pubmed: 30867162
Euro Surveill. 2021 Feb;26(6):
pubmed: 33573712
Euro Surveill. 2020 Nov;25(45):
pubmed: 33183404
J Gerontol A Biol Sci Med Sci. 2021 Feb 25;76(3):e46-e51
pubmed: 33151305
J Infect. 2021 Jan;82(1):e11-e14
pubmed: 32853597
Trans R Soc Trop Med Hyg. 2015 Jan;109(1):9-15
pubmed: 25573105
Obes Med. 2020 Sep;19:100259
pubmed: 32501427
Am J Hematol. 2021 Jul 1;96(7):E257-E259
pubmed: 33837984
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Nature. 1967 Jun 17;214(5094):1224-5
pubmed: 4169229
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
J Infect Dis. 2021 Sep 17;224(6):983-988
pubmed: 33693749
Clin Infect Dis. 2000 Aug;31(2):578-85
pubmed: 10987724
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Ann Rheum Dis. 2021 Jul;80(7):930-942
pubmed: 33504483